Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 71% below its 3-year average of 0.00, near the low end of its 3-year range (0.00–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 48.98% below its 12-month average of 0.00.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-48.98%
CURRENT VS 3Y AVG
-70.79%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 770 covered companies
CURRENT VS SECTOR MEDIAN
-98.70%
vs the sector median at left
Jade Biosciences, Inc.
Market Cap
$804.32M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$790.46M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.03
Market Cap
$782.66M
Debt to Equity Ratio
0.56
TTM Avg
0.77
3Y Avg
0.65
5Y Avg
0.53
Market Cap
$785.70M
Debt to Equity Ratio
1.50
TTM Avg
1.31
3Y Avg
1.32
5Y Avg
1.45
Market Cap
$778.43M
Debt to Equity Ratio
0.75
TTM Avg
0.85
3Y Avg
0.85
5Y Avg
0.87
Market Cap
$770.72M
Debt to Equity Ratio
0.34
TTM Avg
0.66
3Y Avg
0.73
5Y Avg
0.51
Market Cap
$776.41M
Debt to Equity Ratio
0.48
TTM Avg
0.43
3Y Avg
0.36
5Y Avg
0.32
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $804.32M | 0.00 | 0.00 | 0.00 | N/A |
| InMode Ltd. (INMD)vs › | $802.72M | 0.01 | 0.01 | 0.01 | 0.01 |
| Ardelyx, Inc. (ARDX)vs › | $810.26M | 1.72 | 1.08 | 0.72 | 0.64 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $790.46M | 0.03 | 0.02 | 0.02 | 0.03 |
| Geron Corporation (GERN)vs › | $782.66M | 0.56 | 0.77 | 0.65 | 0.53 |
| AdaptHealth Corp. (AHCO)vs › | $785.70M | 1.50 | 1.31 | 1.32 | 1.45 |
| Varex Imaging Corporation (VREX)vs › | $778.43M | 0.75 | 0.85 | 0.85 | 0.87 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.72M | 0.34 | 0.66 | 0.73 | 0.51 |
| Sana Biotechnology, Inc. (SANA)vs › | $776.41M | 0.48 | 0.43 | 0.36 | 0.32 |
| Alumis Inc. (ALMS)vs › | $837.49M | 0.08 | 0.12 | 0.12 | 0.12 |
Debt/Equity
0.00
Current Ratio
14.93
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.01 |
| 2024-09-30 | 0.01 |
| 2024-06-30 | 0.01 |
| 2024-03-31 | 0.01 |
| 2023-12-31 | 0.01 |
| 2023-09-30 | 0.01 |
